Phase 2 N=154 Post-Operative Constipation Following Total Knee Arthroplasty
Constipation
Primary: Bowel Movement (BM) Within 3 Days of Surgery — 29; 32 Participants — p=0.41
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
HIV Infections
Primary: Cmax of Rosuvastatin — 6.70; 16.32 ng/mL
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
Phase 1 N=19 Electrical Stimulation for Critically Ill Covid-19 Patients
Covid19 · Muscle Atrophy · Muscle Weakness
Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts
Phase 2 N=295 Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
COVID-19
Primary: Disease Progression at Day 28 — 10; 6 Participants — p=0.787
Phase 2 N=103 A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
IgA Nephropathy · CKD Associated With Type 1 Diabetes · Focal Segmental Glomerulosclerosis
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 — 9.31; 8.00; 5.46; 7.83 mL/min/1.73 m^2 — p=<0.0001
N/A N=24 Ipsihand Device Use in Stroke Patients to Assess Functional Motor Outcomes
Stroke
Primary: Fugl-Meyer Assessment - Upper Extremity — 9.18 Units on a scale
N/A N=296 An Accessible Digital Intervention to Promote HIV Testing/Counseling and Prevention Among Adolescents
HIV Prevention
Primary: Attitudes Around HIV Testing and Counseling — 0.33; 0.33; 0.74; 0.26 score on a scale
N/A N=5 UVA Light Device to Treat COVID-19
Coronavirus
Primary: Negative Change in Viral Load — 3.2 log10 copies/mL
Phase 3 N=406 Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Type 2 Diabetes Mellitus
Primary: Change in Glycated Hemoglobin (HbA1c) (%) — -0.46; -1.14; -1.48; -1.59 HbA1c (%)
N/A N=32 The Effect of Repeated Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior
Antisocial Behavior · Aggression
Primary: Number of Pins Inserted Into a Virtual Voodoo Doll After 48 Hours — 3.77; .64 pins
N/A N=30 Functional Resistance Training to Improve Knee Function After ACL Reconstruction
Anterior Cruciate Ligament Injury
Primary: Quadriceps Muscle Strength — .674; .398; .279 Nm/Kg
Phase 3 N=424 A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Multiple Sclerosis · Walking Impairment
Primary: Number of Patients With Adverse Events — 122; 116; 86 Participants
Phase 3 N=404 Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
Degenerative Disc Disease
Primary: Overall Treatment Success: Bayesian Estimated Response Rate — 0.267; 0.335; 0.313 BE proportion of participants
N/A N=30 EMR Outcomes: Anxiety and Depression in Epilepsy
Quality of Life · Anxiety · Depression
Primary: Percentage of Participants Retained in the Study in the EMR Arm — 67 percentage of participants